vs
Side-by-side financial comparison of AMPCO PITTSBURGH CORP (AP) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
AMPCO PITTSBURGH CORP is the larger business by last-quarter revenue ($104.4M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 11.5%). AMPCO PITTSBURGH CORP produced more free cash flow last quarter ($-64.0K vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -2.6%).
Ampco-Pittsburgh Corporation is a specialty steel manufacturer headquartered in Downtown Pittsburgh, Pennsylvania. It is one of several companies to bear the Ampco name, and it should not be confused with the Milwaukee-based copper base alloy producer, Ampco Metal Inc.; the Miami-based cabinetry company; the Swiss aluminum corporation; or the Dallas-based tool company. Ampco was formed in 1929 and is a conglomerate made up of several previously established small steel makers. Five small compa...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
AP vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.4M | $86.8M |
| Net Profit | $-57.7M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | -54.0% | -84.7% |
| Net Margin | -55.2% | — |
| Revenue YoY | 11.5% | 17.7% |
| Net Profit YoY | -1958.9% | — |
| EPS (diluted) | $-2.87 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $104.4M | $86.8M | ||
| Q3 25 | $103.7M | $67.5M | ||
| Q2 25 | $108.9M | $60.0M | ||
| Q1 25 | $99.2M | $49.3M | ||
| Q4 24 | $93.6M | $73.7M | ||
| Q3 24 | $92.1M | $58.6M | ||
| Q2 24 | $107.1M | $31.1M | ||
| Q1 24 | $110.0M | $715.0K |
| Q4 25 | $-57.7M | — | ||
| Q3 25 | $-2.2M | $-91.3M | ||
| Q2 25 | $-7.3M | $-111.7M | ||
| Q1 25 | $1.1M | $-116.2M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $-2.0M | $-83.5M | ||
| Q2 24 | $2.0M | $-97.1M | ||
| Q1 24 | $-2.7M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | -54.0% | -84.7% | ||
| Q3 25 | 1.1% | -140.7% | ||
| Q2 25 | -2.8% | -189.8% | ||
| Q1 25 | 3.9% | -245.8% | ||
| Q4 24 | 5.5% | -117.5% | ||
| Q3 24 | 2.0% | -152.1% | ||
| Q2 24 | 4.7% | -327.6% | ||
| Q1 24 | 0.1% | -16464.6% |
| Q4 25 | -55.2% | — | ||
| Q3 25 | -2.1% | -135.3% | ||
| Q2 25 | -6.7% | -186.2% | ||
| Q1 25 | 1.2% | -235.5% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -2.1% | -142.7% | ||
| Q2 24 | 1.9% | -312.2% | ||
| Q1 24 | -2.5% | -15800.8% |
| Q4 25 | $-2.87 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.36 | $-0.33 | ||
| Q1 25 | $0.06 | $-0.36 | ||
| Q4 24 | $0.16 | $-0.24 | ||
| Q3 24 | $-0.10 | $-0.28 | ||
| Q2 24 | $0.10 | $-0.34 | ||
| Q1 24 | $-0.14 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $297.0M |
| Total DebtLower is stronger | $117.9M | — |
| Stockholders' EquityBook value | $32.6M | $698.6M |
| Total Assets | $495.4M | $913.2M |
| Debt / EquityLower = less leverage | 3.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $297.0M | ||
| Q3 25 | $15.0M | $300.8M | ||
| Q2 25 | $9.9M | $301.2M | ||
| Q1 25 | $7.1M | $359.7M | ||
| Q4 24 | $15.4M | $323.8M | ||
| Q3 24 | $11.8M | $397.5M | ||
| Q2 24 | $7.9M | $412.5M | ||
| Q1 24 | $10.8M | $356.2M |
| Q4 25 | $117.9M | — | ||
| Q3 25 | $119.0M | — | ||
| Q2 25 | $115.9M | — | ||
| Q1 25 | $115.0M | — | ||
| Q4 24 | $116.4M | — | ||
| Q3 24 | $116.0M | — | ||
| Q2 24 | $119.4M | — | ||
| Q1 24 | $116.2M | — |
| Q4 25 | $32.6M | $698.6M | ||
| Q3 25 | $60.1M | $702.3M | ||
| Q2 25 | $62.7M | $698.5M | ||
| Q1 25 | $64.6M | $767.9M | ||
| Q4 24 | $58.9M | $710.4M | ||
| Q3 24 | $61.3M | $773.5M | ||
| Q2 24 | $58.0M | $768.5M | ||
| Q1 24 | $56.3M | $680.0M |
| Q4 25 | $495.4M | $913.2M | ||
| Q3 25 | $524.4M | $904.9M | ||
| Q2 25 | $537.2M | $907.4M | ||
| Q1 25 | $536.2M | $966.7M | ||
| Q4 24 | $530.9M | $910.4M | ||
| Q3 24 | $547.4M | $991.1M | ||
| Q2 24 | $560.8M | $964.3M | ||
| Q1 24 | $565.8M | $869.8M |
| Q4 25 | 3.61× | — | ||
| Q3 25 | 1.98× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.78× | — | ||
| Q4 24 | 1.98× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 2.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.7M | $-52.6M |
| Free Cash FlowOCF − Capex | $-64.0K | $-61.9M |
| FCF MarginFCF / Revenue | -0.1% | -71.3% |
| Capex IntensityCapex / Revenue | 2.7% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.1M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.7M | $-52.6M | ||
| Q3 25 | $6.3M | $-78.7M | ||
| Q2 25 | $-2.3M | $-67.4M | ||
| Q1 25 | $-5.3M | $-103.7M | ||
| Q4 24 | $7.5M | $-73.3M | ||
| Q3 24 | $11.4M | $-59.0M | ||
| Q2 24 | $-5.3M | $-98.4M | ||
| Q1 24 | $4.5M | $-122.3M |
| Q4 25 | $-64.0K | $-61.9M | ||
| Q3 25 | $3.3M | $-89.5M | ||
| Q2 25 | $-3.8M | $-74.9M | ||
| Q1 25 | $-7.5M | $-109.9M | ||
| Q4 24 | $3.7M | $-77.5M | ||
| Q3 24 | $8.4M | $-61.3M | ||
| Q2 24 | $-8.0M | $-98.9M | ||
| Q1 24 | $1.7M | $-126.5M |
| Q4 25 | -0.1% | -71.3% | ||
| Q3 25 | 3.2% | -132.7% | ||
| Q2 25 | -3.5% | -124.9% | ||
| Q1 25 | -7.5% | -222.8% | ||
| Q4 24 | 4.0% | -105.1% | ||
| Q3 24 | 9.1% | -104.6% | ||
| Q2 24 | -7.5% | -317.9% | ||
| Q1 24 | 1.5% | -17685.3% |
| Q4 25 | 2.7% | 10.7% | ||
| Q3 25 | 2.9% | 16.1% | ||
| Q2 25 | 1.3% | 12.4% | ||
| Q1 25 | 2.2% | 12.6% | ||
| Q4 24 | 4.0% | 5.7% | ||
| Q3 24 | 3.2% | 3.9% | ||
| Q2 24 | 2.5% | 1.4% | ||
| Q1 24 | 2.6% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -4.62× | — | ||
| Q4 24 | 2.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.64× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
